$0.85
0.38% yesterday
Nasdaq, Aug 12, 10:15 pm CET
ISIN
US4525EP1011
Symbol
IMUX

Immunic, Inc. Stock price

$0.85
+0.01 1.45% 1M
-0.09 9.15% 6M
-0.15 14.78% YTD
-0.48 35.92% 1Y
-4.40 83.77% 3Y
-17.99 95.48% 5Y
-635.95 99.87% 10Y
-479.15 99.82% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.00 0.38%
ISIN
US4525EP1011
Symbol
IMUX
Industry

Key metrics

Basic
Market capitalization
$83.8m
Enterprise Value
$69.5m
Net debt
positive
Cash
$14.3m
Shares outstanding
90.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
45.1%
Return on Equity
-545.4%
ROCE
1,992.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-100.9m | -
EBIT
$-101.0m | $-106.6m
Net Income
$-96.4m | $-67.0m
Free Cash Flow
$-82.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-5.3% | -
EBIT
-5.4% | -8.7%
Net Income
1.6% | 33.4%
Free Cash Flow
-9.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.0
FCF per Share
$-0.9
Short interest
9.1%
Employees
91
Rev per Employee
$0.0
Show more

Is Immunic, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Immunic, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Immunic, Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Immunic, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Immunic, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
8% 8%
-
- Research and Development Expense 83 83
5% 5%
-
-101 -101
5% 5%
-
- Depreciation and Amortization 0.15 0.15
36% 36%
-
EBIT (Operating Income) EBIT -101 -101
5% 5%
-
Net Profit -96 -96
2% 2%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunic, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunic, Inc. Stock News

Positive
Proactive Investors
4 days ago
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's second quarter highlights, with a particular focus on clinical progress in its multiple sclerosis (MS) programs. The headline development was the promising results from the Phase 2 CALLIPER trial of vidofludimus calcium, Immunic's lead asset.
Positive
Proactive Investors
6 days ago
Immunic Inc (NASDAQ:IMUX) said on Thursday it has fully enrolled its twin Phase 3 ENSURE trials for vidofludimus calcium, positioning the company for a major data readout by end-2026 in relapsing multiple sclerosis (RMS). The oral therapy, which activates the Nurr1 nuclear receptor, has shown neuroprotective, anti-inflammatory, and anti-viral properties.
Neutral
The Motley Fool
6 days ago
Immunic (IMUX -0.17%), a late-stage biotechnology company focused on autoimmune and inflammatory diseases, released its second quarter 2025 results on August 7, 2025. The quarter was marked by meaningful clinical progress for its lead product candidate but also persistent financial challenges.
More Immunic, Inc. News

Company Profile

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Head office United States
CEO Daniel Vitt
Employees 91
Founded 2003
Website imux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today